Publications by authors named "Vicky M Coyle"

Claim this Profile
A
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Vicky M Coyle

J Exp Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Kirsty Taylor, Jinfeng Zou, Marcos Magalhaes, Marc Oliva, Anna Spreafico, Vicky M Coyle

Eur J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Aya El Helali, Ruth Plummer, Gordon C Jayson, Vicky M Coyle, Yvette Drew

Br J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Nyree Crawford, Katie J Stott, Tamas Sessler, Christopher McCann, William McDaid, Vicky M Coyle

Mol Cancer Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.
Andrea Lees, Alexander J McIntyre, Nyree T Crawford, Fiammetta Falcone, Christopher McCann, Vicky M Coyle

Proc Natl Acad Sci U S A· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Victoria K Woodcock, Sally Clive, Richard H Wilson, Vicky M Coyle, Michael R L Stratford

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Matthew Alderdice, Philip D Dunne, Aidan J Cole, Paul G O'Reilly, Darragh G McArt, Vicky M Coyle

Mod Pathol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
Donna M Graham, Vicky M Coyle, Richard D Kennedy, Richard H Wilson

Curr Colorectal Cancer Rep· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Donna M Graham, Richard C Turkington, Manuel Salto-Tellez, Vicky M Coyle, Richard H Wilson

J Natl Cancer Inst· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic melanoma: a regional review and future directions.
Khurum H Khan, Rebecca B Goody, Hassan Hameed, Awais Jalil, Vicky M Coyle

Tumori· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Wendy L Allen, Richard C Turkington, Leanne Stevenson, Gail Carson, Vicky M Coyle

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Wendy L Allen, Leanne Stevenson, Vicky M Coyle, Puthen V Jithesh, Irina Proutski

Mol Cancer Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic markers for decision making: what is preventing us from using markers?
Vicky M Coyle, Patrick G Johnston

Nat Rev Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiling of colorectal cancer.
Vicky M Coyle, Patrick G Johnston

Eur J Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Wendy L Allen, Vicky M Coyle, Puthen V Jithesh, Irina Proutski, Leanne Stevenson

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and prognostic markers in colorectal cancer.
Richard C Turkington, Vicky M Coyle, Patrick G Johnston, Martin M Eatock

Per Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the outcome of chemotherapy for colorectal cancer.
Wendy L Allen, Vicky M Coyle, Patrick G Johnston

Curr Opin Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis